Translational initiatives in thrombolytic therapy

Area of Science:

• Biochemistry
• Pharmacology
• Biotechnology

Background:

• Thrombi formation is central to myocardial infarction, stroke, and other embolic disorders.
• Plasminogen activators are key thrombolytic agents that induce fibrinolysis by converting plasminogen to plasmin.
• Recombinant DNA technology enables molecular optimization of thrombolytic efficacy.

Purpose of the Study:

• To review targeted and untargeted thrombolytic formulations investigated in preclinical studies.
• To highlight strategies for mitigating hemorrhagic side effects associated with thrombolytic therapy.

Main Methods:

• Review of preclinical studies on various thrombolytic formulations.
• Analysis of nanoparticulate encapsulation and complexation strategies.
• Examination of molecular optimization and targeting approaches.

Main Results:

• Plasminogen activators are the primary agents for reversing thrombosis.
• Hemorrhagic side effects, particularly intracerebral, remain a significant challenge.
• Nanoparticulate strategies show promise for ameliorating adverse effects.

Conclusions:

• Targeted thrombolytic formulations, often using nanoparticles, are under active investigation.
• Reducing bleeding complications is crucial for advancing thrombolytic therapy.
• Further preclinical research is needed to optimize these novel formulations.